Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN AND FAMOTIDINE vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis,Management of ankylosing spondylitis,Dysmenorrhea,Mild to moderate pain,Reduction of fever,Off-label: Migraine, gout, acute musculoskeletal pain
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
1 drop in the affected eye(s) four times daily
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (Cr Cl <10 m L/min).
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Famotidine is minimally metabolized in the liver (30-35%) via oxidative pathways; the remainder is excreted unchanged in urine.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Ibuprofen: >99% bound to albumin (mostly). Famotidine: 15-20% bound to plasma proteins (albumin).
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding and limited tissue distribution). Famotidine: 1.1-1.4 L/kg (suggests extensive extravascular distribution).
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Ibuprofen: Oral: 80-100% (well absorbed with food causing slight delay). Famotidine: Oral: 40-50% (first-pass metabolism; reduced with food).
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
Contraindicated if Cr Cl < 30 m L/min. For Cr Cl 30-49 m L/min, reduce famotidine dose by 50% (not possible with fixed combination; use alternative therapy).
No dosage adjustment required for renal impairment
No specific dose adjustment for Child-Pugh A or B; avoid in severe hepatic impairment (Child-Pugh C) due to ibuprofen component.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Not established for combination; ibuprofen 5-10 mg/kg/dose (max 400 mg) q6-8h as separate agent; famotidine 0.5 mg/kg/dose (max 20 mg) q12h for pediatric use.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Start at lowest effective dose; monitor renal function; avoid if Cr Cl < 30 m L/min; increased risk of GI bleeding and renal impairment.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
None
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events. Gastrointestinal risk: Serious GI adverse events including bleeding, ulceration, and perforation. Renal toxicity: Monitor renal function. Hepatic effects: Elevation of liver enzymes. Anaphylactoid reactions: Bronchospasm in aspirin-sensitive asthma. Hypertension: Can worsen blood pressure control. Fluid retention and edema.
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
History of allergic reaction to ibuprofen, famotidine, or any other NSAID. History of aspirin-sensitive asthma. Coronary artery bypass graft (CABG) surgery. Active peptic ulcer disease or GI bleeding. Advanced renal disease. Pregnancy at 30 weeks gestation and later (risk of premature closure of ductus arteriosus).
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Avoid alcohol; increases GI bleeding risk. No other significant food interactions. Take with food or milk to reduce gastric irritation.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low risk, but limited data. Second trimester: Ibuprofen use is linked to fetal renal dysfunction and oligohydramnios; famotidine appears safe. Third trimester: Ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension; famotidine has no known fetal risks.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Ibuprofen: Excretion into breast milk is low (M/P ratio 0.007-0.24); considered compatible with breastfeeding. Famotidine: Excreted in breast milk (M/P ratio approximately 0.25-0.71); infant exposure is low; generally acceptable with caution. Combined use: Limited data; monitor infant for gastrointestinal effects.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
Ibuprofen: No standard dose adjustment; avoid in third trimester. Famotidine: No dose adjustment required. Combined product: Avoid in third trimester; use lowest effective dose and shortest duration in first/second trimester.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Ibuprofen and famotidine combination tablet (Duexis) is used for osteoarthritis and rheumatoid arthritis to reduce GI ulcer risk. Do not exceed 800 mg ibuprofen per dose or 3200 mg per day. Famotidine component provides gastric protection; additional acid suppression not needed. Avoid in advanced renal disease, active GI bleeding, or COX-2 inhibitor allergy. Monitor renal function, BP, and signs of GI bleeding. Dual COX/5-LOX inhibition by ibuprofen raises cardiovascular thrombotic risk; use lowest effective dose.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Take with food or milk to reduce stomach upset.,Do not take more than 3 tablets per day (each tablet contains 800 mg ibuprofen).,May cause drowsiness or dizziness; avoid driving if affected.,Report black/tarry stools, vomiting blood, chest pain, or leg swelling immediately.,Avoid alcohol and other NSAIDs (e.g., aspirin, naproxen) while taking this medication.,Inform all healthcare providers you are taking this drug, especially before surgery.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN AND FAMOTIDINE vs ACULAR LS, answered by our medical review team.
IBUPROFEN AND FAMOTIDINE is a NSAID that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN AND FAMOTIDINE and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN AND FAMOTIDINE is: One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN AND FAMOTIDINE and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN AND FAMOTIDINE is classified as Category D/X. First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low ri. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.